Search

New data exchange platform on rare diseases

The European Commission (EC) launched a new online knowledge-sharing platform – the European Platform on Rare Disease Registration (EU RD Platform) – on February 28, 2019.

Read more

EHA-GBMTA-AHA Hematology Tutorial

EHA is joining the Georgian Association for Blood and Bone Marrow Transplantation (GBMTA) and Armenian Hematology Association (AHA) to organize the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies.

Read more

Registration & accommodation

Registration is now closed

Individual registrationHybrid registration includes:

In-person access to the scientific and educational sessions of the meeting
Access to the virtual platform
Meeting materials
Coffee/tea breaks on February 9-11, 2023 and lunches on February 10 & 11
Access to the Welcome Reception
Access to the…

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

EHA Statement: Our sustained solidarity with the hematology community in Ukraine

Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.

Read more

Guidelines for hematologists

For guidance regarding COVID-19, see FAQ by the EHA SWG on Infections

EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases.

Read more

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…

Read more